In the wake of continued efforts made in research, development and production, the biomedical park in the Taizhou Medical High-tech Zone, located in Taizhou city, East China's Jiangsu province, has made fresh progress in developing innovative products.
One pathfinder in this is Qyuns Therapeutics, established in the zone in 2015, which specializes in the biological therapy of autoimmune and allergic diseases.
Recently, the first domestically produced Ustekinumab injection, developed by Qyuns Therapeutics and Hangzhou Zhongmeihuadong Pharmaceutical, received an acceptance notice issued by the National Medical Products Administration, or NMPA.
This meant that the product's marketing authorization application and supplementary application for Crohn's disease had been accepted.
On Feb 12, Jiangsu Recbio Technology in the park, an innovative vaccine company focusing on independent research and development, also received an acceptance notice issued by the NMPA.
The administration agreed to accept its independently developed new adjuvant recombinant nine valent HPV vaccine REC604c clinical trial application.
An exterior view of Jiangsu Recbio Technology. [Photo/WeChat account: weigg6666]
REC604c is a new recombinant nine valent HPV vaccine that the company plans to develop for the male and upgrade markets.
Another player, Jiangsu Anbison Pharmaceutical, was founded in the zone in 2019. Not long ago, the company's levetiracetam and cytarabine for injection products obtained the marketing approval issued by the NMPA.
The two products will be used in additional treatment for partial seizures in epilepsy patients aged 12 and above, as well as for induction remissions and maintenance therapy for acute non-lymphocytic leukemia in adults and children, respectively.